Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Raises $74M in Public Offering

NEW YORK (GenomeWeb News) – Luminex has closed its public offering of 4,025,000 shares of common stock, including the over-allotment option of 525,000 shares, raising roughly $74.3 million in net proceeds.
 
The offering was priced at $19.91 per share, which was Luminex’s closing price on June 24. In late Monday afternoon trade, the firm’s shares were down .5 percent at $20.68.
 
Luminex said in its preliminary prospectus for the offering that net proceeds will be used for general corporate purposes, including research and development, potential acquisitions of, or investments in, companies and technologies, capital expenditures, and additions to working capital.
 
JPMorgan and UBS are joint book-running managers for the offering, with Avondale Partners, Canaccord Adams, Leerink Swann acting as co-managers.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.